Health Care·Biotechnology·$5.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.54 | N/A | -34.33% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.54 | N/A | -34.33% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management's commentary reflected a cautious approach, highlighting ongoing challenges. They reiterated their commitment to long-term goals.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term strategies despite current setbacks.
The earnings report indicates that Mirum Pharmaceutical is struggling with its earnings performance, as evidenced by the EPS miss. The stock reacted negatively, dropping 3.36% in response to the disappointing results. Investors may be concerned about the lack of revenue figures and forward guidance, which adds uncertainty to the company's outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AECOM
May 6, 2024